A new medication for heavy bleeding associated with uterine fibroids has received FDA approval. In this article, Ob/Gyn Linda Bradley, MD, discusses the results of the phase 3 trials.
A Cleveland Clinic gynecology team investigates versican proteolysis to further explain the pathogenesis of leiomyomas, perhaps offering a new therapeutic direction for this very common malady.
Many women with large uterine fibroids achieved dramatic relief from their symptoms while on the progesterone receptor modulator vilaprisan. Next step: Phase 3 trial to begin early 2017.